Jefferies analyst Brian Tanquilut downgraded Option Care Health (OPCH) to Hold from Buy with a price target of $26, down from $38. The analyst believes uncertainty with the pricing dynamics for Stelara will persist over the next few months and keep the shares range-bound. Citi significant margin compression for Stelara, Jefferies reduced 2025 EBIDTA estimates by 5%. It now sees lower visibility into Option Care’s underlying growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health Reports Q3 Revenue Surge Amid Challenges
- Option Care Health downgraded to Neutral at BofA on Stelara risks
- Option Care Health downgraded to Neutral from Buy at BofA
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- Option Care Health sees ‘drastic,’ ‘rapid’ impact in early 2025 from biosimilars